



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

**Reagent:** GAG-1 $\alpha$  (102-117)

**Catalog Number:** 1463

**Lot Number:** 6/4/92

**Provided:** 100  $\mu$ g, 1.0 mg/ml. Dilutions should be made in 10 mM carbonate buffer, pH 9.6 (Sigma, Catalog #C3041).

**Sequence:** PPSSPTHDPDSDPQI.

**Special Characteristics:** Residues 102-117 from HTLV-I p19 Gag. Gag-1 $\alpha$  represents the immunodominant C-terminal of HTLV-I p19<sup>gag</sup>. This peptide is recognized by 92% of all HTLV-I and 9% of all HTLV-II sera tested.

[Protocol: ELISA for Detection of HTLV-I and HTLV-II Positive Sera](#)

**Recommended Storage:** -70°C.

**Contributor:** Dr. Renu B. Lal.

**References:** Lal RB, Rudolph DL, Griffis KP, Kitamura K, Honda M, Coligan JE, Folks TM. Characterization of immunodominant epitopes of *gag* and *pol* gene-encoded proteins of human T-cell lymphotropic virus type I. *J Virol* **65**:1870-1876, 1991.

Lal RB, Brodine SK, Coligan JE, Roberts CR. Differential antibody responsiveness to p19 Gag results in serological discrimination between human T lymphotropic virus type I and type II. *J Med Virol* **35**:232-236, 1991.

**NOTE:** Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: GAG-1 $\alpha$ <sup>102-117</sup> from Dr. Renu Lal." Also include the references cited above in any publications.

A US Government Patent (#5738805) has been issued on this research material. Scientists at for-profit institutions or who intend commercial use of this reagent must contact Ms. Lisa Blake-DiSpigna at email address [LBlake-DiSpigna@cdc.gov](mailto:LBlake-DiSpigna@cdc.gov) and specify in the email the name of the reagent, and a description of the intended use of the

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

reagent.

**Last Updated:**

August 11, 2015

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.